Transcode Therapeutics Valuation
| RNAZ Stock | USD 8.98 0.32 3.44% |
At this time, the company appears to be fairly valued. Transcode Therapeutics has a current Real Value of $8.93 per share. The regular price of the company is $8.98. Our model measures the value of Transcode Therapeutics from inspecting the company fundamentals such as Shares Outstanding of 916.97 K, shares owned by institutions of 7.15 %, and Return On Equity of -17.63 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Transcode Therapeutics' valuation include:
Fairly Valued
Today
Please note that Transcode Therapeutics' price fluctuation is moderately volatile at this time. Calculation of the real value of Transcode Therapeutics is based on 3 months time horizon. Increasing Transcode Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Transcode Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Transcode Stock. However, Transcode Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.98 | Real 8.93 | Target 10.0 | Hype 9.37 | Naive 8.68 |
The intrinsic value of Transcode Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Transcode Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Transcode Therapeutics helps investors to forecast how Transcode stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Transcode Therapeutics more accurately as focusing exclusively on Transcode Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Transcode Therapeutics' intrinsic value based on its ongoing forecasts of Transcode Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Transcode Therapeutics' closest peers.
Transcode Therapeutics Cash |
|
Transcode Therapeutics Total Value Analysis
Transcode Therapeutics is at this time forecasted to have valuation of 3.83 M with market capitalization of 8.7 M, debt of 38.29 K, and cash on hands of 13.45 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Transcode Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
3.83 M | 8.7 M | 38.29 K | 13.45 M |
Transcode Therapeutics Asset Utilization
One of the ways to look at asset utilization of Transcode is to check how much profit was generated for every dollar of assets it reports. Transcode Therapeutics has a negative utilization of assets of -2.33 %, losing $0.0233 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Transcode Therapeutics shows how discouraging it operates for each dollar spent on its assets.Transcode Therapeutics Profitability Analysis
Based on Transcode Therapeutics' profitability indicators, Transcode Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Transcode Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2019-12-31 | Previous Quarter -4.3 M | Current Value -4.9 M | Quarterly Volatility 2.8 M |
For Transcode Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Transcode Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Transcode Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Transcode Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Transcode Therapeutics over time as well as its relative position and ranking within its peers.
Transcode Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Transcode Therapeutics is estimated to be 0.0 with future projections ranging from a low of 0.0 to a high of 0.0. Transcode Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -236.52. Please be aware that the consensus of earnings estimates for Transcode Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Transcode Therapeutics Earnings Estimation Breakdown
The calculation of Transcode Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Transcode Therapeutics is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Transcode Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Transcode Therapeutics Earnings Projection Consensus
Suppose the current estimates of Transcode Therapeutics' value are higher than the current market price of the Transcode Therapeutics stock. In this case, investors may conclude that Transcode Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Transcode Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 1 | 55.97% | -5.13 | 0.0 | -236.52 |
Transcode Therapeutics Ownership Allocation
Transcode Therapeutics has 9.2 % of its outstanding shares held by insiders and 7.15 % owned by institutional holders.Transcode Therapeutics Profitability Analysis
Net Loss for the year was (16.75 M) with profit before overhead, payroll, taxes, and interest of 0.About Transcode Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Transcode Therapeutics. We calculate exposure to Transcode Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Transcode Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -481.4 K | -457.3 K |
Transcode Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Transcode Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Transcode we look at many different elements of the entity such as Transcode's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Transcode Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Transcode Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Transcode Therapeutics' worth.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.